Sarepta Soars on Q2 Earnings & Sales Beat, Resumes Elevidys Deliveries

Key Takeaways Sarepta Therapeutics, Inc. (SRPT) reported second-quarter 2025 adjusted EPS of $2.02, which beat the Zacks Consensus Estimate of $1.11. This beat was mainly due to higher-than-expected collaboration revenues coupled with lower operating expenses incurred during the quarter. In the year-ago period, the company posted an adjusted EPS of 43 cents. The adjusted figures exclude depreciation and amortization costs, stock-based compensation expenses and gains on strategic investments. Including these ...